BridgeBio Oncology Therapeutics (BBOT) vs Perspective Therapeutics (CATX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Perspective Therapeutics (CATX) has outperformed BridgeBio Oncology Therapeutics (BBOT) over the past year, losing 29.1% versus a loss of 71.8%. Perspective Therapeutics is the larger company by market cap ($280.8 million vs $275.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBOT | CATX |
|---|---|---|
| Share price | $3.44 | $2.46 |
| Market cap | $275.80M | $280.81M |
| 1-day change | -1.71% | +4.24% |
| YTD return | -72.52% | -10.55% |
| 1-year return | -71.83% | -29.11% |
| 5-year return | — | -60.32% |
| EPS (TTM) | $-0.07 | $-1.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.87 | $6.16 |
| 52-week low | $3.36 | $1.96 |
| Distance from 52-week high | -76.87% | -60.06% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +613.66% | +399.59% |
| Average volume | 471.17K | 1.68M |
| Shares outstanding | 80.17M | 114.15M |
| Employees | 88 | 163 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CATX has outperformed BBOT by 42.7 percentage points over the past year.
About BridgeBio Oncology Therapeutics
BBOT stock →BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
BBOT vs CATX FAQ
Which is bigger, BridgeBio Oncology Therapeutics or Perspective Therapeutics?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $280.81M compared with $275.80M for BridgeBio Oncology Therapeutics (BBOT).
Which stock has performed better over the past year, BBOT or CATX?
CATX returned -29.11% over the past 12 months, compared with -71.83% for BBOT (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Oncology Therapeutics and Perspective Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.